A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, fo ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Novartis has announced a five-year commitment to the fight against malaria, saying it plans to invest more than $100m to advance R&D of next-generation drugs for the disease becomes resistant to ...

A reasonable jury could find two former Celgene executives acted with fraudulent intent by failing to tell shareholders about a risk the Food and Drug Administration would reject the drug application, ...

Novartis will give Lindy $20 million up front and potentially up to $934 million in milestone and royalty payments. Lindy’s technology, which it calls “microglassification,” makes biologic ...

Novartis has set its sights on the North Carolina biotech ... at home using the Sensoready autoinjector pen to treat patients with relapsing forms of multiple sclerosis. However, the companies said ...